Health Canada has released a new guidance document, How to apply for market authorization for a non-prescription drug in Canada, providing industry with its first comprehensive roadmap for obtaining market authorization for non-prescription drugs (NPDs). While the guidance does not introduce new regulatory requirements, it consolidates several long-standing guidance documents and regulatory processes into a single resource, making it significantly easier for manufacturers to determine the appropriate submission pathway and understand the information required to support safety, efficacy, and quality.
The guidance explains when sponsors should file an Application for a Drug Identification Number (DINA), a Category IV Drug Identification Number Application (DINF), a New Drug Submission (NDS), or an Abbreviated New Drug Submission (ANDS), while also outlining key procedural requirements such as the Regulatory Enrolment Process (REP), electronic submission formats, review timelines, and pre-submission meetings.
Released as part of Health Canada’s broader non-prescription drug regulatory modernization initiative, the document represents an important step toward simplifying market access while improving regulatory transparency. Companies developing or introducing OTC medicines into the Canadian market should familiarize themselves with this guidance to better plan their regulatory strategy and reduce avoidable delays during the submission process.
For decades, companies seeking market authorization for non-prescription drugs in Canada have faced a regulatory landscape that was both comprehensive and fragmented. While Health Canada has long maintained detailed guidance covering Drug Identification Numbers (DINs), New Drug Submissions (NDSs), Category IV products, administrative procedures, and post-market changes, this information has traditionally been spread across numerous guidance documents, policies, and web resources developed over many years.
Determining the correct regulatory pathway often required sponsors to navigate multiple documents simultaneously before they could confidently determine which submission type applied to their product or what supporting information would be expected. This complexity has been particularly challenging for companies entering the Canadian market for the first time, organizations transitioning products from other jurisdictions, and manufacturers with limited experience navigating Canada’s non-prescription drug framework.
Health Canada’s newly published How to apply for market authorization for a non-prescription drug in Canada addresses this longstanding gap by bringing together the most common market authorization pathways into a single guidance document. Rather than replacing existing regulations or introducing new evidentiary standards, the guidance serves as a centralized roadmap that helps applicants understand which submission pathway to use, what information is required, and how the overall authorization process works.
Importantly, the guidance arrives at a time when Health Canada is actively modernizing the regulatory framework for both Natural Health Products (NHPs) and non-prescription drugs. Through its broader Regulating Natural and Non-prescription Health Products: The Path Forward initiative, the department has acknowledged that the current Food and Drug Regulations governing non-prescription drugs have become increasingly complex and, in many cases, apply the same regulatory framework to both prescription and non-prescription medicines. Health Canada has identified this as an area where modernization can improve flexibility, reduce unnecessary burden, and facilitate innovation while continuing to protect public health.
As part of this modernization effort, Health Canada has committed to simplifying application requirements, introducing more flexible and risk-based approaches to regulation, and improving the overall market authorization process for non-prescription drugs. The publication of this guidance represents one of the first tangible deliverables supporting that objective.
Although the guidance itself does not create new regulatory obligations, it provides something industry has long lacked: a practical, end-to-end explanation of how the various regulatory pathways fit together. By consolidating existing expectations into a single reference document, Health Canada has made it considerably easier for sponsors to plan submissions, identify applicable requirements early, and avoid unnecessary regulatory uncertainty.
For regulatory affairs professionals, the value of the guidance is therefore less about changing the rules and more about making those rules significantly easier to navigate.
The new guidance is intended to assist sponsors seeking initial market authorization for most non-prescription drugs sold in Canada. Its primary purpose is to help applicants determine the appropriate submission type while explaining the evidence required to demonstrate a product’s safety, efficacy, and quality. It also provides an overview of Health Canada’s submission process, including intake requirements, electronic filing expectations, and supporting resources available throughout the review process.
The guidance focuses on the four submission pathways that account for the vast majority of non-prescription drug applications submitted to the Natural and Non-prescription Health Products Directorate (NNHPD):
In addition to explaining when each pathway should be used, the guidance introduces applicants to several foundational components of Health Canada’s regulatory process, including:
The guidance also helps clarify an important distinction that often causes confusion among sponsors: whether a product should be regulated under Division 1 or Division 8 of the Food and Drug Regulations. While both pathways ultimately lead to market authorization, they differ significantly in terms of the regulatory evidence required and the review process followed by Health Canada. Understanding this distinction early in product development can have a substantial impact on submission strategy, timelines, and overall development costs.
It is equally important to understand what the guidance does not cover. The document is primarily intended for products that have not yet received market authorization and therefore does not serve as a comprehensive guide to post-market lifecycle management. Certain products, including ethical drugs that may be available without a prescription in specific settings, also fall outside its scope. For those situations, Health Canada continues to direct sponsors to existing guidance documents covering DIN requirements, post-Notice of Compliance quality changes, and administrative processing procedures.
By clearly defining both its scope and its relationship to existing guidance documents, Health Canada has positioned this publication as the central starting point for companies preparing to bring a new non-prescription drug to the Canadian market. Rather than replacing established guidance, it provides a practical framework for understanding how those documents work together within the broader regulatory system—a welcome improvement for both experienced regulatory professionals and companies navigating Canada’s market authorization process for the first time.
One of the primary objectives of Health Canada’s new guidance is to help sponsors determine which regulatory pathway is appropriate for their product before preparing a submission. While the underlying regulatory requirements have existed for many years, they have often been spread across multiple guidance documents, making it difficult—particularly for new applicants—to confidently identify the correct submission type.
The guidance consolidates these pathways into a single resource and explains when each should be used, the level of evidence typically expected, and how products are authorized under either Division 1 or Division 8 of the Food and Drug Regulations.
Although every product must ultimately demonstrate that it is safe, effective, and of appropriate quality, the amount and type of supporting information required varies considerably depending on the novelty of the product and the evidence already available.
The table below provides a high-level comparison of the four most common authorization pathways.
| Submission Type | Typically Used For | Regulatory Basis |
| DINF | Products that fully comply with an established Category IV Monograph | Division 1 |
| DINA | Non-prescription drugs supported by existing evidence, labelling standards, or published scientific literature | Division 1 |
| NDS | Novel non-prescription drugs or products requiring a full scientific review | Division 8 |
| ANDS | Generic versions of previously authorized drugs demonstrating equivalence | Division 8 |
While these categories may appear straightforward, selecting the wrong submission pathway can result in unnecessary review delays, requests for additional information, or the need to refile under a different regulatory activity. For this reason, sponsors should evaluate the applicable pathway early in product development rather than after preparing their submission.
Before determining which application to prepare, sponsors must first establish whether their product falls under Division 1 or Division 8 of the Food and Drug Regulations.
In general, Division 1 applications apply to products that can be authorized using existing regulatory standards, established monographs, recognized labelling standards, or previously accepted scientific evidence. These submissions generally receive a Drug Identification Number (DIN) without requiring the extensive scientific review associated with a new drug.
By contrast, Division 8 applies to products considered new drugs under the Regulations. These products require a much more comprehensive review of safety, efficacy, and quality before Health Canada will issue both a Notice of Compliance (NOC) and a Drug Identification Number (DIN).
Although the distinction sounds simple, determining whether a product qualifies as a Division 1 or Division 8 drug is often one of the earliest and most important strategic decisions in the regulatory process.
Selecting a DINA, DINF, NDS, or ANDS is only one part of determining the regulatory pathway for a non-prescription drug. Health Canada also assigns a submission class based on the type and extent of information required to support the application. This classification determines the applicable evaluation fee and is relevant to Health Canada’s performance standards for reviewing the submission.
For example, qualifying DINA and DINF applications that attest to compliance with a Health Canada Labelling Standard or Category IV Monograph fall under the same DIN application submission class, provided they do not include additional clinical, non-clinical, or chemistry and manufacturing data. For NDS and ANDS pathways, the applicable class—and therefore the fee—varies depending on the evidence Health Canada must evaluate.
Health Canada evaluation fees for 2026–2027 include:
| NPD Pathway / Example | Submission Class | Fee |
| DINA – Labelling Standard* | DIN – Labelling Standards | $1,945 |
| DINF – Category IV Monograph* | DIN – Labelling Standards | $1,945 |
| NDS – new active substance | New Active Substance | $616,593 |
| NDS – clinical/non-clinical + C&M data | Clinical/Non-clinical + C&M | $319,282 |
| ANDS – comparative studies | Comparative Studies | $71,953 |
| ANDS – C&M data only | C&M Data Only | $44,269 |
*Where the application meets the applicable Labelling Standard or Category IV Monograph without additional supporting clinical/non-clinical or C&M data.
If more than one submission class applies, Health Canada applies the class with the highest associated fee. Review timelines also vary according to the applicable regulatory activity and performance standard, making both cost and timing important considerations when selecting and planning an NPD submission pathway.
A Drug Identification Number Application (DINA) is the most common pathway for many non-prescription drugs that do not qualify as Category IV products but are nevertheless supported by sufficient existing evidence.
Rather than requiring extensive new clinical studies, these applications typically rely on existing scientific literature, recognized pharmacopoeial standards, established labelling standards, or previously accepted evidence demonstrating that the product is safe, effective, and manufactured to appropriate quality standards.
Examples may include products that:
Although DINA submissions generally require less evidence than a New Drug Submission, sponsors are still expected to provide sufficient information to support the product’s safety, efficacy, quality, formulation, manufacturing, and labelling.
For many established OTC medicines, the DINA pathway represents the balance between regulatory efficiency and appropriate scientific oversight.
Among the four pathways, the Category IV Drug Identification Number Application (DINF) is typically the most streamlined.
Category IV Monographs describe classes of well-established non-prescription drugs for which Health Canada has already determined acceptable medicinal ingredients, strengths, dosage forms, indications, warnings, and directions for use. Products that fully comply with all applicable monograph requirements can generally follow this abbreviated pathway.
Because Health Canada has already evaluated the evidence supporting these monographs, sponsors are not required to resubmit extensive scientific evidence, provided the product remains fully within the published parameters.
However, the guidance also makes it clear that this streamlined process depends on complete compliance with the applicable Category IV Monograph. If a sponsor wishes to introduce claims, formulations, ingredients, strengths, or directions outside those established parameters, a different submission pathway may be required.
For manufacturers of conventional over-the-counter medicines, this pathway continues to provide one of the fastest routes to market authorization.
Products that cannot rely on existing regulatory standards or previously accepted evidence generally require a New Drug Submission (NDS).
These submissions are intended for products considered new drugs under Division 8 of the Food and Drug Regulations. Unlike Division 1 applications, an NDS requires a comprehensive scientific review of the product’s safety, efficacy, and quality before Health Canada will issue a Notice of Compliance.
Examples may include products involving:
Because these submissions involve significantly more complex scientific assessments, Health Canada notes that sponsors may benefit from requesting an optional pre-submission meeting to discuss their proposed evidence package before filing. These meetings can help identify potential issues early, improve submission quality, and reduce review delays for novel products.
For companies developing innovative OTC medicines, early regulatory planning is often essential to determining the scope of evidence that will ultimately be required.
The fourth pathway covered in the guidance is the Abbreviated New Drug Submission (ANDS).
This pathway is generally intended for generic non-prescription drugs that seek market authorization by demonstrating equivalence to an already authorized Canadian Reference Product rather than generating an entirely new body of clinical evidence.
Instead of independently establishing safety and efficacy, ANDS applications focus on demonstrating that the proposed generic product is pharmaceutically equivalent and, where required, bioequivalent to the reference product.
Although abbreviated relative to a full New Drug Submission, these applications remain scientifically rigorous and require detailed supporting information regarding quality, manufacturing, and equivalence.
For manufacturers introducing generic OTC medicines, the ANDS pathway provides an established regulatory mechanism for bringing equivalent products to market while avoiding unnecessary duplication of clinical studies.
While the guidance explains each submission type individually, one of its broader messages is that regulatory strategy begins well before an application is filed.
The choice between a DINF, DINA, NDS, or ANDS influences nearly every aspect of product development—from evidence generation and clinical planning to manufacturing documentation, submission format, review timelines, and overall regulatory costs.
By consolidating these pathways into a single guidance document, Health Canada has made the initial planning process considerably more transparent. Sponsors can now evaluate potential submission routes earlier, identify the information that will be required, and develop a regulatory strategy that aligns with both their product and commercialization timelines.
For organizations introducing new non-prescription drugs into Canada—particularly international manufacturers unfamiliar with the Canadian regulatory framework—this centralized approach should make the market authorization process more predictable and easier to navigate.
While the new guidance does not introduce new evidentiary requirements, it does reinforce another important message: successful market authorization begins well before a submission reaches Health Canada’s review queue.
Throughout the document, Health Canada places considerable emphasis on the procedural aspects of the submission process, including the Regulatory Enrolment Process (REP), electronic filing requirements, pre-submission planning, and performance standards. Rather than treating these as administrative formalities, the guidance positions them as integral components of an efficient regulatory strategy.
For example, sponsors are reminded that every application begins with the Regulatory Enrolment Process (REP), which assigns the company and dossier identifiers needed before a submission can be filed. The guidance also outlines the electronic submission formats accepted by Health Canada—including when the internationally recognized electronic Common Technical Document (eCTD) format is required—and highlights optional pre-submission meetings for novel or complex products. These meetings provide sponsors with an opportunity to discuss proposed evidence packages, identify potential issues early, and improve the overall quality of a submission before formal review begins.
For experienced regulatory teams, many of these processes will already be familiar. However, by presenting them within the broader context of market authorization, the guidance provides a much clearer picture of how each step contributes to the overall review process.
One of the most valuable aspects of the guidance is not the introduction of new regulatory expectations, but the consolidation of multiple long-standing guidance documents into a single, practical resource.
Rather than requiring sponsors to navigate separate documents covering DIN submissions, Drug Identification Numbers, post-Notice of Compliance quality changes, administrative processing, and related procedures, Health Canada now provides a centralized starting point that links these resources together and explains when each becomes relevant.
This is particularly beneficial for companies entering the Canadian market for the first time. International manufacturers are often familiar with regulatory frameworks such as the U.S. FDA’s OTC Monograph System or the European Union’s medicinal product approval pathways, but Canada’s combination of Division 1 and Division 8 requirements, DINs, Notices of Compliance, Category IV Monographs, and Labelling Standards can appear considerably more complex.
By organizing these concepts into a logical decision-making framework, Health Canada has made the Canadian regulatory system significantly easier to understand without changing the underlying regulations themselves.
In many respects, the guidance functions as a regulatory roadmap rather than a new rulebook.
For manufacturers, regulatory affairs professionals, and companies planning to introduce non-prescription drugs into Canada, the publication of this guidance should be viewed as an opportunity to improve regulatory planning rather than a trigger for immediate compliance changes.
Because the document consolidates existing processes rather than establishing new obligations, companies with established regulatory programs are unlikely to require significant changes to their current submission practices. However, organizations should consider reviewing their internal procedures to ensure they align with the terminology, submission pathways, and planning approach described throughout the guidance.
The guidance is likely to provide the greatest value for:
By encouraging sponsors to identify the appropriate submission pathway early, understand filing expectations before development is complete, and make greater use of available regulatory resources, Health Canada is promoting a more predictable and efficient authorization process for both applicants and reviewers.
Health Canada’s new How to apply for market authorization for a non-prescription drug in Canada guidance represents an important milestone in the ongoing modernization of Canada’s non-prescription drug regulatory framework.
While the document does not fundamentally change how non-prescription drugs are regulated, it significantly improves how those requirements are communicated. By bringing together multiple guidance documents into a single reference, Health Canada has created a clearer, more accessible roadmap for companies navigating the market authorization process.
The guidance also reflects a broader shift toward greater regulatory transparency. Rather than expecting sponsors to piece together requirements from numerous policies and guidance documents, Health Canada is providing a more structured framework that helps applicants understand the regulatory journey from initial planning through market authorization.
As Health Canada continues to modernize the regulation of both Natural Health Products and non-prescription drugs, guidance documents like this one will play an increasingly important role in helping industry navigate evolving expectations while supporting more efficient access to the Canadian market.
For companies planning to introduce new over-the-counter medicines in Canada, understanding the appropriate authorization pathway at the outset can help reduce unnecessary delays, improve submission quality, and streamline the overall regulatory process. Whether pursuing a streamlined Category IV application or preparing a complex New Drug Submission, investing time in regulatory strategy early remains one of the most effective ways to support a successful market authorization.
Selecting the appropriate regulatory pathway is one of the most important decisions made during non-prescription drug development. An incorrect submission strategy can lead to avoidable information requests, review delays, or the need to refile under a different regulatory activity. dicentra’s pharmaceutical regulatory affairs team supports manufacturers throughout the market authorization process, from determining the appropriate submission pathway and developing regulatory strategies to preparing complete submission packages and managing Health Canada interactions. Whether your product requires a DINA, DINF, NDS, or ANDS, our regulatory specialists can help navigate the requirements efficiently while supporting timely market access in Canada.
Contact dicentra today for assistance with your NPD market access strategy.